ADAPT SERON Trial Shows Positive Results for Seronegative gMG
Written by
American Journal Managed Care
Published
0
comments
0
min
Efgartigimod shows promise as a groundbreaking treatment for seronegative generalized myasthenia gravis (gMG), addressing a critical unmet need in patient care.